| A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo L Bai, H Zhou, R Xu, Y Zhao, K Chinnaswamy, D McEachern, J Chen, ... Cancer cell 36 (5), 498-511. e17, 2019 | 420 | 2019 |
| Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer X Han, C Wang, C Qin, W Xiang, E Fernandez-Salas, CY Yang, M Wang, ... Journal of medicinal chemistry 62 (2), 941-964, 2019 | 324 | 2019 |
| Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of … C Qin, Y Hu, B Zhou, E Fernandez-Salas, CY Yang, L Liu, D McEachern, ... Journal of medicinal chemistry 61 (15), 6685-6704, 2018 | 241 | 2018 |
| Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable … Y Li, J Yang, A Aguilar, D McEachern, S Przybranowski, L Liu, CY Yang, ... Journal of medicinal chemistry 62 (2), 448-466, 2018 | 240 | 2018 |
| Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER) J Hu, B Hu, M Wang, F Xu, B Miao, CY Yang, M Wang, Z Liu, DF Hayes, ... Journal of medicinal chemistry 62 (3), 1420-1442, 2019 | 222 | 2019 |
| Discovery of highly potent and efficient PROTAC degraders of androgen receptor (AR) by employing weak binding affinity VHL E3 ligase ligands X Han, L Zhao, W Xiang, C Qin, B Miao, T Xu, M Wang, CY Yang, ... Journal of medicinal chemistry 62 (24), 11218-11231, 2019 | 166 | 2019 |
| Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein H Zhou, L Bai, R Xu, Y Zhao, J Chen, D McEachern, K Chinnaswamy, ... Journal of medicinal chemistry 62 (24), 11280-11300, 2019 | 154 | 2019 |
| Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein M Wang, J Lu, M Wang, CY Yang, S Wang Journal of medicinal chemistry 63 (14), 7510-7528, 2020 | 113 | 2020 |
| Formation of a nickel− methyl species in methyl-coenzyme M reductase, an enzyme catalyzing methane formation N Yang, M Reiher, M Wang, J Harmer, EC Duin Journal of the American Chemical Society 129 (36), 11028-11029, 2007 | 89 | 2007 |
| Design of the first‐in‐class, highly potent irreversible inhibitor targeting the menin‐MLL protein–protein interaction S Xu, A Aguilar, T Xu, K Zheng, L Huang, J Stuckey, K Chinnaswamy, ... Angewandte Chemie 130 (6), 1617-1621, 2018 | 59 | 2018 |
| High-affinity peptidomimetic inhibitors of the DCN1-UBC12 protein–protein interaction H Zhou, W Zhou, B Zhou, L Liu, TR Chern, K Chinnaswamy, J Lu, ... Journal of Medicinal Chemistry 61 (5), 1934-1950, 2018 | 54 | 2018 |
| Structure-based discovery of CF53 as a potent and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor Y Zhao, B Zhou, L Bai, L Liu, CY Yang, JL Meagher, JA Stuckey, ... Journal of medicinal chemistry 61 (14), 6110-6120, 2018 | 32 | 2018 |
| Uptake of Glycerol-2-Phosphate via the ugp-Encoded Transporter in Escherichia coli K-12 K Yang, M Wang, WW Metcalf Journal of bacteriology 191 (14), 4667-4670, 2009 | 32 | 2009 |
| 氯乙酰化聚苯乙烯型固相载体的制备 魏荣卿， 王强， 刘晓宁， 王迷， 欧阳平凯 离子交换与吸附 21 (4), 289-296, 2005 | 30 | 2005 |
| SD-91 as a potent and selective STAT3 degrader capable of achieving complete and long-lasting tumor regression H Zhou, L Bai, R Xu, D McEachern, K Chinnaswamy, R Li, B Wen, ... ACS Medicinal Chemistry Letters 12 (6), 996-1004, 2021 | 27 | 2021 |
| EEDi-5285: An exceptionally potent, efficacious, and orally active small-molecule inhibitor of embryonic ectoderm development RK Rej, C Wang, J Lu, M Wang, E Petrunak, KP Zawacki, D McEachern, ... Journal of medicinal chemistry 63 (13), 7252-7267, 2020 | 26 | 2020 |
| A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo A Kaneshige, L Bai, M Wang, D McEachern, JL Meagher, R Xu, Y Wang, ... Nature Chemical Biology 19 (6), 703-711, 2023 | 21 | 2023 |
| Changing the apoptosis pathway through evolutionary protein design D Shultis, P Mitra, X Huang, J Johnson, NA Khattak, F Gray, C Piper, ... Journal of molecular biology 431 (4), 825-841, 2019 | 18 | 2019 |
| Discovery of EEDi-5273 as an exceptionally potent and orally efficacious EED inhibitor capable of achieving complete and persistent tumor regression RK Rej, C Wang, J Lu, M Wang, E Petrunak, KP Zawacki, D McEachern, ... Journal of medicinal chemistry 64 (19), 14540-14556, 2021 | 15 | 2021 |
| Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy J Deng, A Paulus, DD Fang, A Manna, G Wang, H Wang, S Zhu, J Chen, ... Clinical Cancer Research 28 (24), 5455-5468, 2022 | 14 | 2022 |
